Skip to main content
SpringerLink
Log in

Cytokines in Rheumatoid Arthritis

Potential Targets for Pharmacological Intervention

  • Review Article
  • Clinical Pharmacology
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Summary

The ingress of inflammatory leucocytes into the synovium is a crucial step in the pathogenesis of rheumatoid arthritis (RA). Cytokines are mediators involved in the inflammatory events, adhesive mechanisms, angiogenesis and osteopenia associated with RA. Pro- and anti-inflammatory cytokines, growth factors and chemokines all have an important role in these processes. Because the efficacy of currently used antirheumatic therapy is often limited, there is a need for more specific intervention strategies. Anticytokine therapy may include the use of monoclonal antibodies, antagonistic cytokines, soluble cytokine receptors, cytokine receptor antagonists, somatic gene transfer or other approaches. Hopefully, the study of cytokines and their interactions will lead to the development of new immunomodulatory strategies that will benefit patients with RA.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Harris Jr ED. Rheumatoid arthritis: pathophysiology and implications for therapy. N Engl J Med 1990; 332: 1277–87

    Google Scholar 

  2. Koch AE, Kunkel SL, Strieter RM. Cytokines in rheumatoid arthritis. J Invest Med 1995; 43: 28–38

    CAS  Google Scholar 

  3. Brennan FM, Field M, Chu CQ, et al. Cytokine expression in rheumatoid arthritis. Br J Rheumatol 1991; 30: 76–80

    PubMed  Google Scholar 

  4. Firestein GS, Alvaro-Garcia JM, Maki R. Quantitative analysis of cytokine gene expression in rheumatoid arthritis. J Immunol 1990; 144: 3347–53

    PubMed  CAS  Google Scholar 

  5. Firestein GS. The immunopathogenesis of rheumatoid arthritis. Curr Opin Rheumatol 1991; 3: 398–406

    PubMed  CAS  Google Scholar 

  6. Lipsky PE, Davis LS, Cush JJ, et al. The role of cytokines in the pathogenesis of rheumatoid arthritis. Springer Semin Immunopathol 1989; 11: 123–62

    PubMed  CAS  Google Scholar 

  7. Szekanecz Z, Szegedi G, Koch AE. Cellular adhesion molecules in rheumatoid arthritis: regulation by cytokines and possible clinical importance. J Invest Med 1996; 44: 124–35

    CAS  Google Scholar 

  8. Szekanecz Z, Halloran MM, Haskell CJ, et al. Mediators of angiogenesis: the role of cellular adhesion molecules. Trends Glycosci Glycotechnol. In press

  9. Colville-Nash PR, Scott DL. Angiogenesis in rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51: 919–25

    PubMed  CAS  Google Scholar 

  10. Haskard DO. Cell adhesion molecules in rheumatoid arthritis. Curr Opin Rheumatol 1995; 7: 229–34

    PubMed  CAS  Google Scholar 

  11. Canalis E. Regulation in bone remodeling. In: Favus MJ, editor. Primer on the metabolic bone diseases and disorders of mineral metabolism. Kelseyville: American Society for Bone and Mineral Research, 1990: 23–6

    Google Scholar 

  12. Manolagas SC, Jilka RL. Bone marrow, cytokines, and bone remodeling: emerging insights into the pathophysiology of osteoporosis. N Engl J Med 1995; 332: 305–11

    PubMed  CAS  Google Scholar 

  13. Joffe I, Epstein S. Osteoporosis associated with rheumatoid arthritis: pathogenesis and management. Semin Arthritis Rheum 1991; 20: 256–72

    PubMed  CAS  Google Scholar 

  14. Tannenbaum H. Osteopenia in rheumatology practice: pathogenesis and therapy. Semin Arthritis Rheum 1984; 13: 337–48

    PubMed  CAS  Google Scholar 

  15. Taki H, Sugiyama E, Mino T, et al. Spontaneous production of interleukin-11 and its inhibition by indomethacin and dexamethasone in freshly isolated rheumatoid synoviocytes [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129

    Google Scholar 

  16. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu Rev Immunol 1996; 14: 397–440

    PubMed  CAS  Google Scholar 

  17. Feldman M, Elliott MJ, Woody JN, et al. Anti-tumor necrosis factor-α therapy of rheumatoid arthritis. In: Dixon FJ, editor. Advances in immunology. Vol. 64. London: Academic Press, 1997: 283–350

    Google Scholar 

  18. Barrera P, Boerbooms AMT, van de Putte LBA, et al. Effects of antirheumatic agents on cytokines. Semin Arthritis Rheum 1996; 25: 234–53

    PubMed  CAS  Google Scholar 

  19. Dayer J-M, Arend WP. Cytokines and growth factors. In: Kelle WN, Harris ED, Ruddy S, et al., editors. Textbook of rheumatology. 5th ed. Philadelphia: Saunders, 1997: 267–86

    Google Scholar 

  20. Dayer J-M, de Rochemonteix B, Burrus B, et al. Human recombinant interleukin 1 stimulates collagenase and prostaglandin E2 production by human synovial cells. J Clin Invest 1986; 77: 645–8

    PubMed  CAS  Google Scholar 

  21. McCachren S, Greer PK, Niedel JE. Regulation of human synovial fibroblast collagenase messenger RNA by interleukin-1. Arthritis Rheum 1989; 32: 1539–45

    PubMed  CAS  Google Scholar 

  22. Leizer T, Clarris BJ, Ash PE, et al. Interleukin-1 beta and interleukin-1 alpha stimulate the plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum 1987; 30: 562–6

    PubMed  CAS  Google Scholar 

  23. Postlethwaite AE, Raghow R, Stricklin GP, et al. Modulation of fibroblast functions by interleukin 1: increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin 1 alpha and beta. J Cell Biol 1988; 106: 311–8

    PubMed  CAS  Google Scholar 

  24. Goldring MB, Birkheak J, Sandeil LJ, et al. Interleukin 1 suppresses expression of cartilage and specific types I and III collagens in human chondrocytes. J Clin Invest 1988; 82: 2026–37

    PubMed  CAS  Google Scholar 

  25. Dalton BJ, Connor JR, Johnson WJ. Interleukin-1 induces interleukin-1 alpha and interleukin-1 beta gene expression in synovial fibroblasts and peripheral blood monocytes. Arthritis Rheum 1989; 32: 279–87

    PubMed  CAS  Google Scholar 

  26. Guerne P-A, Zuraw BL, Vaughan JH, et al. Synovium as a source of interleukin 6 in vitro. J Clin Invest 1989; 83: 585–92

    PubMed  CAS  Google Scholar 

  27. Koch AE, Kunkel SL, Burrows JC, et al. Synovial tissue macrophage as a source of the chemotactic cytokine IL-8. J Immunol 1991; 147: 2187–95

    PubMed  CAS  Google Scholar 

  28. Koch AE, Kunkel SL, Harlow LA, et al. Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992; 90: 772–9

    PubMed  CAS  Google Scholar 

  29. Sunderkötter C, Steinbrink K, Goebeler M, et al. Macrophages and angiogenesis. J Leukoc Biol 1994; 55: 410–22

    PubMed  Google Scholar 

  30. Abbot SE, Kaul A, Stevens CR, et al. Isolation and culture of synovial microvascular endothelial cells: characterization and assessment of adhesion molecule expression. Arthritis Rheum 1992; 35: 401–6

    PubMed  CAS  Google Scholar 

  31. Lindsley HB, Smith DD, Davis LS, et al. Regulation of the expression of adhesion molecules by human synoviocytes. Semin Arthritis Rheum 1992; 21: 330–4

    PubMed  CAS  Google Scholar 

  32. Bellido T, Jilka RL, Boyce BF, et al. Regulation of interleukin-6, osteoclastogenesis and bone mass by androgens: the role of the androgen receptor. J Clin Invest 1995; 95: 2886–95

    PubMed  CAS  Google Scholar 

  33. Bismar H, Diel I, Ziegler R, et al. Increased cytokine secretion by human bone marrow cells after menopause or discontinuation of estrogen replacement. J Clin Endocrinol Metab 1995; 80: 3351–5

    PubMed  CAS  Google Scholar 

  34. Horowitz MC. Cytokines and estrogen in bone. Science 1993; 260: 626–8

    PubMed  CAS  Google Scholar 

  35. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257: 88–91

    PubMed  CAS  Google Scholar 

  36. Buchan G, Barrett K, Turner M, et al. Interleukin-1 and tumour necrosis factor mRNA expression in rheumatoid arthritis: prolonged production of IL-1 alpha. Clin Exp Immunol 1988; 73: 449–55

    PubMed  CAS  Google Scholar 

  37. Nouri AM, Panayi GS, Goodman SM. Cytokines and the chronic inflammation of rheumatic disease: I. The presence of interleukin-1 in synovial fluids. Clin Exp Immunol 1984; 55: 295–302

    PubMed  CAS  Google Scholar 

  38. Shore A, Jaglal S, Keystone EC. Enhanced interleukin 1 generation by monocytes in vitro is temporally linked to an early event in the onset or exacerbation of rheumatoid arthritis. Clin Exp Immunol 1986; 65: 293–302

    PubMed  CAS  Google Scholar 

  39. Strieter RM, Kunkel SL, Bone RC. Role of tumor necrosis factor-α in disease states and inflammation. Crit Care Med 1993; 21(10): S447–63

    PubMed  CAS  Google Scholar 

  40. Dayer J-M, Beutler B, Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J Exp Med 1985; 162: 2163–8

    PubMed  CAS  Google Scholar 

  41. Koch AE, Kunkel SL, Harlow LA, et al. Macrophage inflammatory protein-1α: a novel chemotactic cytokine for macrophages in rheumatoid arthritis. J Clin Invest 1994; 93: 921–8

    PubMed  CAS  Google Scholar 

  42. Koch AE, Kunkel SL, Harlow LA, et al. Epithelial neutrophil activating peptide-78: a novel chemotactic cytokine for neutrophils in arthritis. J Clin Invest 1994; 94: 1012–8

    PubMed  CAS  Google Scholar 

  43. Tessier P, Audette M, Cattaruzzi P, et al. Up-regulation by tumour necrosis factor-α of intercellular adhesion molecule 1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum 1993; 36: 1528–39

    PubMed  CAS  Google Scholar 

  44. Leibovich SJ, Polverini PJ, Shepard HM, et al. Macrophage-induced angiogenesis is mediated by tumour necrosis factor-α. Nature 1987; 329: 630–2

    PubMed  CAS  Google Scholar 

  45. Bertolini DR, Nedwin GE, Bringman TS, et al. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumour necrosis factors. Nature 1986; 319: 516–8

    PubMed  CAS  Google Scholar 

  46. Saxne T, Palladino Jr MA, Heinegard D, et al. Detection of tumor necrosis factor a but not tumor necrosis factor β in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 1988; 31: 1041–5

    PubMed  CAS  Google Scholar 

  47. Chu CQ, Field M, Feldmann M, et al. Localization of tumor necrosis factor α in synovial tissues and at the cartilagepannus junction in patients with rheumatoid arthritis. Arthritis Rheum 1991; 34: 1125–32

    PubMed  CAS  Google Scholar 

  48. Manicourt D-H, Triki R, Fukuda K, et al. Levels of circulating tumor necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Arthritis Rheum 1993; 36: 490–9

    PubMed  CAS  Google Scholar 

  49. Roubenoff R, Roubenoff RA, Ward LM, et al. Rheumatoid cachexia: depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J Rheumatol 1992; 19: 1505–10

    PubMed  CAS  Google Scholar 

  50. Tetta C, Camussi G, Modena V, et al. Tumor necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665–7

    PubMed  CAS  Google Scholar 

  51. Wong GG, Clark SC. Multiple actions of interleukin 6 within a cytokine network. Immunol Today 1988; 9: 137–9

    PubMed  CAS  Google Scholar 

  52. Le J, Vilcrek J. Interleukin 6: a multifunctional cytokine regulating immune reactions and the acute phase protein response. Lab Invest 1989; 61: 588–602

    PubMed  CAS  Google Scholar 

  53. Motro B, Itin A, Sachs L, et al. Pattern of interleukin-6 gene expression in vivo suggests a role for this cytokine in angiogenesis. Proc Natl Acad Sci U S A 1990; 87: 3092–6

    PubMed  CAS  Google Scholar 

  54. Rosen EM, Liu D, Setter E, et al. Interleukin-6 stimulates motility of vascular endothelium. EXS 1991; 59: 194–205

    PubMed  CAS  Google Scholar 

  55. Houssiau FA, Devogelaer J-P, Van Damme J, et al. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1988; 31: 784–8

    PubMed  CAS  Google Scholar 

  56. Helle M, Boeije L, de Groot E, et al. Sensitive ELISA for interleukin-6 detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods 1991; 138: 47–56

    PubMed  CAS  Google Scholar 

  57. Waage A, Kaufmann C, Espevik T, et al. Interleukin-6 in synovial fluid from patients with arthritis. Clin Immunol Immunopathol 1989; 50: 394–8

    PubMed  CAS  Google Scholar 

  58. Madhok R, Crilly A, Murphy E, et al. Gold therapy lowers serum interleukin 6 levels in rheumatoid arthritis. J Rheumatol 1993; 20: 630–3

    PubMed  CAS  Google Scholar 

  59. Tan PLJ, Farmiloe S, Yeoman S, et al. Expression of the interleukin 6 gene in rheumatoid synovial fibroblasts. J Rheumatol 1990; 17: 1608–12

    PubMed  CAS  Google Scholar 

  60. Field M, Chu C, Feldmann M, et al. Interleukin-6 localisation in the synovial membrane in rheumatoid arthritis. Rheumatol Int 1991; 11: 45–50

    PubMed  CAS  Google Scholar 

  61. Miossec P. Pro- and antiinflammatory cytokine balance in rheumatoid arthritis. Clin Exp Rheumatol 1995; 13Suppl. 12P: S13–6

    PubMed  Google Scholar 

  62. van Roon JA, van Roy JL, Gmelig-Meyling FH, et al. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996; 39: 829–35

    PubMed  Google Scholar 

  63. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. J Immunol 1995; 154: 1432–9

    PubMed  CAS  Google Scholar 

  64. Vannier E, de Waal-Malefyt R, Salazar-Montes A, et al. Interleukin-13 (IL-13) induces IL-1 receptor antagonist gene expression and protein synthesis in peripheral blood mononuclear cells: inhibition by an IL-4 mutant protein. Blood 1996; 87: 3307–15

    PubMed  CAS  Google Scholar 

  65. Klareskog L, Ronnelid J, Holm G. Immunopathogenesis and immunotherapy in rheumatoid arthritis: an area in transition. J Intern Med 1995; 238: 191–206

    PubMed  CAS  Google Scholar 

  66. Sugiyama E, Kuroda A, Taki H, et al. Interleukin 10 cooperates with interleukin 4 to suppress inflammatory cytokine production by freshly prepared adherent rheumatoid synovial cells. J Rheumatol 1995; 22: 2020–6

    PubMed  CAS  Google Scholar 

  67. Koch AE, Fong TW, Volpert OV, et al. Interleukin-4 is an inhibitor of angiogenesis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S304

    Google Scholar 

  68. Bizzarri C, Shioi A, Teitelbaum SL, et al. Interleukin-4 inhibits bone resorption and acutely increases cytosolic Ca2+ in murine osteoclasts. J Biol Chem 1994; 269: 13817–24

    PubMed  CAS  Google Scholar 

  69. Katsikis PD, Chu CQ, Brennan FM, et al. Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med 1994; 179: 1517–27

    PubMed  CAS  Google Scholar 

  70. Lacraz S, Nicod LP, Chicheportiche R, et al. IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J Clin Invest 1995; 96: 2304–10

    PubMed  CAS  Google Scholar 

  71. Owens JM, Gallagher AC, Chambers TJ. IL-10 modulates formation of osteoclasts in murine hemopoietic cultures. J Immunol 1996; 157: 936–40

    PubMed  CAS  Google Scholar 

  72. Isomaki P, Luukkainen R, Toivanen P, et al. The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1693–702

    PubMed  CAS  Google Scholar 

  73. Woods JM, Haines GK, Shah MR, et al. Interleukin-13 in synovial fluid and tissue of patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129

    Google Scholar 

  74. Halloran MM, Hosaka S, Woods JM, et al. A new function for interleukin-13 as an endothelial chemotaxin [abstract]. Arthritis Rheum 1996; 39 Suppl.: S129

    Google Scholar 

  75. McInnes IB, A1-Mughales J, Field M, et al. The role of interleukin-15 in T cell migration and activation in rheumatoid arthritis. Nature Med 1996; 2: 175–82

    PubMed  CAS  Google Scholar 

  76. Campbell IK, Waring P, Novak U, et al. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor a. Arthritis Rheum 1993; 36: 790–4

    PubMed  CAS  Google Scholar 

  77. Pepper MS, Ferrara N, Orci L, et al. Leukemia inhibitory factor (LIF) inhibits angiogenesis in vitro. J Cell Sci 1995; 108: 73–83

    PubMed  CAS  Google Scholar 

  78. Waring PM, Carroll GJ, Kandiah DA, et al. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum 1993; 36: 911–5

    PubMed  CAS  Google Scholar 

  79. Hamilton JA, Waring PM, Filonzi EL. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α. J Immunol 1993; 150: 1496–502

    PubMed  CAS  Google Scholar 

  80. Villiger PM, Geng Y, Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J Clin Invest 1993; 91: 1575–81

    PubMed  CAS  Google Scholar 

  81. Wisniewski HG, Maier R, Lotz M, et al. TSG-6: a TNF-, IL-1-, and LPS-inducible secreted glycoprotein associated with arthritis. J Immunol 1993; 151: 6593–601

    PubMed  CAS  Google Scholar 

  82. Alvaro-Gracia JM, Zvaifler MNJ, Brown CB, et al. Analysis of the synovial cells involved in granulocyte-macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α. J Immunol 1991; 146: 3365–71

    PubMed  CAS  Google Scholar 

  83. Alvaro-Garcia JM, Zvaifler NJ, Firestein GS. Granulocyte/macrophage colony-stimulating factor–mediated induction of class II MHC antigen on human monocytes: a possible role in rheumatoid arthritis. J Exp Med 1989; 170: 865–75

    Google Scholar 

  84. Leizer T, Cebon J, Layton JE, et al. Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 1990; 76: 1989–96

    PubMed  CAS  Google Scholar 

  85. Remmers EF, Sano H, Wilder RL. Platelet-derived growth factors and heparin-binding (fibroblast) growth factors in the synovial tissue pathology of rheumatoid arthritis. Semin Arthritis Rheum 1991; 21: 191–9

    PubMed  CAS  Google Scholar 

  86. Sato N, Beitz JG, Kato J, et al. Platelet-derived growth factor indirectly stimulates angiogenesis in vitro. Am J Pathol 1993; 142: 1119–30

    PubMed  CAS  Google Scholar 

  87. Lafyatis R, Remmers EF, Roberts AB, et al. Anchorage-independent growth of synoviocytes from arthritic and normal joints. J Clin Invest 1989; 83: 1267–76

    PubMed  CAS  Google Scholar 

  88. Koch AE, Harlow LA, Haines GK, et al. Vascular endothelial growth factor: a cytokine modulating endothelial function in rheumatoid arthritis. J Immunol 1994; 152: 4149–56

    PubMed  CAS  Google Scholar 

  89. Klagsbrun M, D’Amore PA. Regulators of angiogenesis. Annu Rev Physiol 1991; 53: 217–39

    PubMed  CAS  Google Scholar 

  90. Sano H, Forough R, Maier JAM, et al. Detection of high levels of heparin binding growth factor-1 (acidic fibroblast growth factor) in inflammatory arthritic joints. J Cell Biol 1990; 110: 1417–26

    PubMed  CAS  Google Scholar 

  91. Goddard DH, Grossman SL, Williams WV, et al. Regulation of synovial cell growth: coexpression of transforming growth factor β and basic fibroblast growth factor by cultured synovial cells. Arthritis Rheum 1992; 35: 1296–303

    PubMed  CAS  Google Scholar 

  92. Takeuchi M, Otsuka T, Matsui N, et al. Aberrant production of gliostatin/platelet-derived endothelial cell growth factor in rheumatoid synovium. Arthritis Rheum 1994; 37: 662–72

    PubMed  CAS  Google Scholar 

  93. Auerbach W, Auerbach R. Angiogenesis inhibition: a review. Pharmacol Ther 1994; 63: 265–311

    PubMed  CAS  Google Scholar 

  94. Wiseman DM, Polverini PJ, Kamp DW, et al. Transforming growth factor-beta (TGFβ) is chemotactic for human monocytes and induces their expression of angiogenic activity. Biochem Biophys Res Commun 1988; 157: 793–800

    PubMed  CAS  Google Scholar 

  95. Chu CQ, Field M, Abney E, et al. Transforming growth factor-β1 in rheumatoid synovial membrane and cartilage/pannus junction. Clin Exp Immunol 1991; 86: 380–6

    PubMed  CAS  Google Scholar 

  96. Szekanecz Z, Haines GK, Harlow LA, et al. Increased synovial expression of transforming growth factor (TGF)-β receptor endoglin and TGF-β1 in rheumatoid arthritis: possible interactions in the pathogenesis of the disease. Clin Immunol Immunopathol 1995; 76: 187–94

    PubMed  CAS  Google Scholar 

  97. Wahl SM, Allen JB, Wong HL, et al. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J Immunol 1990; 145: 2514–9

    PubMed  CAS  Google Scholar 

  98. Gunther M, Haubeck HD, van de Leur E, et al. Transforming growth factor beta 1 regulates tissue inhibitor of metalloproteinases-1 expression in differentiated human articular chondrocytes. Arthritis Rheum 1994; 37: 395–405

    PubMed  CAS  Google Scholar 

  99. Wahl SM, Costa GL, Corcoran M, et al. Transforming growth factor-beta mediates IL-1-dependent induction of IL-1 receptor antagonist. J Immunol 1993; 150: 3553–60

    PubMed  CAS  Google Scholar 

  100. Fava RA, Olsen NJ, Postlethwaite AE, et al. Transforming growth factor β1 (TGF-β1) induced neutrophil recruitment to synovial tissues: implications for TGF-β-driven synovial inflammation and hyperplasia. J Exp Med 1991; 173: 1121–32

    PubMed  CAS  Google Scholar 

  101. Brandes ME, Allen JB, Ogawa Y, et al. Transforming growth factor β1 suppresses acute and chronic arthritis in experimental animals. J Clin Invest 1991; 87: 1108–13

    PubMed  CAS  Google Scholar 

  102. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter factor induces blood vessel formation in vivo. Proc Natl Acad Sci U S A 1993; 90: 1937–41

    PubMed  CAS  Google Scholar 

  103. Koch AE, Halloran MM, Hosaka S, et al. Hepatocyte growth factor: a cytokine mediating endothelial migration in inflammatory arthritis. Arthritis Rheum 1996; 39: 1566–75

    PubMed  CAS  Google Scholar 

  104. Walz A, Kunkel SL, Strieter RM. C-X-C chemokines–an overview. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 1–25

    Google Scholar 

  105. Taub DD. C-C chemokines–an overview. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 27–54

    Google Scholar 

  106. Kunkel SL, Lukacs N, Kasama T, et al. The role of chemokines in inflammatory joint disease. J Leukoc Biol 1996; 58: 6–12

    Google Scholar 

  107. Oppenheim JJ, Zachariae COC, Mukaida N, et al. Properties of the novel proinflammatory supergene ‘intercrine’ cytokine family. Annu Rev Immunol 1991; 9: 617–48

    PubMed  CAS  Google Scholar 

  108. Koch AE, Kunkel SL, Strieter RM. Chemokines in arthritis. In: Koch AE, Strieter RM, editors. Chemokines in disease. Austin (TX): RG Landes Company, 1996: 103–16

    Google Scholar 

  109. Peichl P, Ceska M, Effenberger F, et al. Presence of NAP-1/IL-8 in synovial fluids indicates a possible pathogenic role in rheumatoid arthritis. Scand J Immunol 1991; 34: 333–9

    PubMed  CAS  Google Scholar 

  110. Rampart M, Herman AG, Grillet B, et al. Development and application of a radioimmunoassay for interleukin-8: detection of interleukin-8 in synovial fluids from patients with inflammatory joint disease. Lab Invest 1992; 66: 512–8

    PubMed  CAS  Google Scholar 

  111. Endo H, Akahoshi T, Takagishi K, et al. Elevation of interleukin-8 (IL-8) levels in joint fluids of patients with rheumatoid arthritis and the induction by IL-8 of leukocyte infiltration and synovitis in rabbit joints. Lymphokine Cytokine Res 1991; 10(4): 245–52

    PubMed  CAS  Google Scholar 

  112. Koch AE, Polverini PJ, Kunkel SL, et al. Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science 1992; 258: 1798–801

    PubMed  CAS  Google Scholar 

  113. Hu DE, Hori Y, Fan T-PD. Interleukin-8 stimulates angiogenesis in rats. Inflammation 1993; 17: 135–43

    PubMed  CAS  Google Scholar 

  114. Castor CW, Andrews PC, Swartz RD, et al. The origin, variety, distribution, and biologic fate of connective tissue activating peptide-III isoforms: characteristics in patients with rheumatic, renal, and arterial disease. Arthritis Rheum 1993; 36: 1142–53

    PubMed  CAS  Google Scholar 

  115. Bedard PA, Golds EE. Cytokine-induced expression of mRNAs for chemotactic factors in human synovial cells and fibroblasts. J Cell Physiol 1993; 154: 433–41

    PubMed  CAS  Google Scholar 

  116. Koch AE, Kunkel SL, Shah MR, et al. Growth-related gene product alpha: a chemotactic cytokine for neutrophils in rheumatoid arthritis. J Immunol 1995; 155: 3660–6

    PubMed  CAS  Google Scholar 

  117. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992; 149: 722–7

    PubMed  CAS  Google Scholar 

  118. Hachicha M, Rathanaswami P, Schall TJ, et al. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Arthritis Rheum 1993; 36: 26–34

    PubMed  CAS  Google Scholar 

  119. Taub DD, Conlon K, Lloyd AR, et al. Preferential migration of activated CD4+ and CD8+ T cells in response to MIP-1α and MIP-lβ. Science 1993; 260: 355–8

    PubMed  CAS  Google Scholar 

  120. Akahoshi T, Wada C, Endo H, et al. Expression of monocyte chemotactic and activating factor in rheumatoid arthritis. Arthritis Rheum 1993; 36: 762–71

    PubMed  CAS  Google Scholar 

  121. Fahey III TJ, Tracey KJ, Tekamp-Olson P, et al. Macrophage inflammatory protein 1 modulates macrophage function. J Immunol 1991; 148: 2764–9

    Google Scholar 

  122. Koch AE, Kunkel SL, Shah MR, et al. Macrophage inflammatory protein-1 beta: a C-C chemokine in osteoarthritis. Clin Immunol Immunopathol 1995; 77: 307–14

    PubMed  CAS  Google Scholar 

  123. Schall TJ, Bacon K, Toy KJ, et al. Selective attraction of monocytes and T lymphocytes of the memory phenotype by cytokine RANTES. Nature 1990; 347: 669–71

    PubMed  CAS  Google Scholar 

  124. Rathanaswami P, Hachicha M, Sadick M, et al. Expression of the cytokine RANTES in human rheumatoid synovial fibroblasts. J Biol Chem 1993; 268: 5834–9

    PubMed  CAS  Google Scholar 

  125. Robinson E, Keystone EC, Schall TJ, et al. Chemokine expression in rheumatoid arthritis (RA): evidence of RANTES and macrophage inflammatory protein (MIP)-1 beta production by synovial T cells. Clin Exp Immunol 1995; 101: 398–407

    PubMed  CAS  Google Scholar 

  126. Arend WP, Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum 1990; 33: 305–15

    PubMed  CAS  Google Scholar 

  127. Evans CH, Robbins PD. Pathways to gene therapy in rheumatoid arthritis. Curr Opin Rheumatol 1996; 8: 230–4

    PubMed  CAS  Google Scholar 

  128. Nita I, Ghivizzani SC, Galea-Lauri J, et al. Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996; 39: 820–8

    PubMed  CAS  Google Scholar 

  129. Kingsley G, Panayi G, Lanchbury J. Immunotherapy of rheumatic diseases–practice and prospects. Immunol Today 1991; 12: 177–9

    PubMed  CAS  Google Scholar 

  130. Kalden JR, Manger B. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996; 8: 195–200

    PubMed  CAS  Google Scholar 

  131. Rankin ECC, Choy EHS, Kassimos D, et al. The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. Br J Rheumatol 1995; 34: 334–42

    PubMed  CAS  Google Scholar 

  132. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor α antibody in rheumatoid arthritis. Arthritis Rheum 1996; 39: 1082–91

    PubMed  CAS  Google Scholar 

  133. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1077–81

    PubMed  CAS  Google Scholar 

  134. Wendling D, Racadot E, Wijdenes J. Treatment of severe rheumatoid arthritis by anti-interleukin 6 monoclonal antibody. J Rheumatol 1993; 20: 259–62

    PubMed  CAS  Google Scholar 

  135. Kyle V, Coughlan RJ, Tighe H. Beneficial effect of monoclonal antibody to interleukin-2 receptor on activated T cells in rheumatoid arthritis. Ann Rheum Dis 1989; 48: 428–9

    PubMed  CAS  Google Scholar 

  136. Harris Jr ED. Treatment of rheumatoid arthritis. In: Kelley WN, Harris Jr ED, Russy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1996: 912–23

    Google Scholar 

  137. American College of Rheumatology ad hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. Arthritis Rheum 1996; 39: 713–22

    Google Scholar 

  138. Goodwin JS. Nonsteroidal antiinflammatory drugs. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1959–67

    Google Scholar 

  139. Cash JM, Hoffman GS. Glucocorticoids. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1947–58

    Google Scholar 

  140. Cash JM, Hoffman GS. Immunomodulatory pharmaceuticals. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1980–92

    Google Scholar 

  141. Thomas R, Carroll GJ. Reduction of leukocyte and interleukin-1 beta concentrations in the synovial fluid of rheumatoid arthritis patients treated with methotrexate. Arthritis Rheum 1993; 36: 1244–52

    PubMed  CAS  Google Scholar 

  142. Danis VA, Franic GM, Rathjen DA, et al. Circulating cytokine levels in patients with rheumatoid arthritis: results of a double blind trial with sulphasalazine. Ann Rheum Dis 1992; 51: 946–50

    PubMed  CAS  Google Scholar 

  143. Dougados M. Cyclosporin in rheumatoid arthritis. Clin Exp Rheumatol 1994; 12Suppl. 11: S75–8

    PubMed  Google Scholar 

  144. Fagrinoli S, van Thiel DH. Immunophillin binding agents. In: Rich RR, Fleisher TA, Schwartz BD, et al., editors. Clinical immunology: principles and practice. St Louis (MO): Mosby, 1996: 1993–2001

    Google Scholar 

  145. Ho S, Clipstone N, Timmermann L, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol 1996; 80: S40–5

    PubMed  CAS  Google Scholar 

  146. Fauci AS, Young Jr KR. Immunomodulatory agents. In: Kelley WN, Harris Jr ED, Russy S, et al., editors. Textbook of rheumatology. Philadelphia: Saunders, 1996: 797–821

    Google Scholar 

  147. Girasole G, Jilka RL, Passed G, et al. 17β-Estradiol inhibits interleukin-6 production by bone marrow-derived stromal cells and osteoblasts in vitro: a potential mechanism for the antiosteoporotic effect of estrogens. J Clin Invest 1992; 89: 883–91

    PubMed  CAS  Google Scholar 

  148. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. Arthritis Rheum 1994; 37: 1499–505

    PubMed  CAS  Google Scholar 

  149. Lemire JM, Archer DC, Beck L, et al. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995; 125 Suppl.: 1704S–8S

    PubMed  CAS  Google Scholar 

  150. Lacey DL, Erdmann JM, Tan HL, et al. Murine osteoblast interleukin 4 receptor expression: upregulation by 1,25 dihydroxyvitamin D3. J Cell Biochem 1993; 53: 122–34

    PubMed  CAS  Google Scholar 

  151. Pennanen N, Lapinjoki S, Urtti A, et al. Effect of liposomal and free bisphosphonates on the IL-1 beta, IL-6 and TNF alpha secretion from RAW 264 cells in vitro. Pharm Res 1995; 12: 916–22

    PubMed  CAS  Google Scholar 

  152. Choy EHS. Clinical pharmacology and therapeutic potential of monoclonal antibody treatment in rheumatoid arthritis. Drugs Aging 1998; 12: 139–48

    PubMed  CAS  Google Scholar 

  153. Keffer J, Probert L, Cazlaris H, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025–31

    PubMed  CAS  Google Scholar 

  154. Williams RO, Feldmann M, Maini RN. Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784–8

    PubMed  CAS  Google Scholar 

  155. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1993; 36: 1681–90

    PubMed  CAS  Google Scholar 

  156. Brennan FM, Jackson A, Chantry D, et al. Inhibitory effect of TNF-α antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. Lancet 1989; I: 244–7

    Google Scholar 

  157. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-fusion protein. N Engl J Med 1997; 337: 141–97

    PubMed  CAS  Google Scholar 

  158. Drevlow BE, Lovis R, Hang R, et al. Recombinant human interleukin-1 receptor type I in the treatment of patients with active rheumatoid arthritis. Arthritis Rheum 1996; 39: 257–65

    PubMed  CAS  Google Scholar 

  159. Seckinger P, Lowenthal JW, Williamson K, et al. A urine inhibitor of interleukin 1 activity that blocks ligand binding. J Immunol 1987; 139: 1546–9

    PubMed  CAS  Google Scholar 

  160. Carter DB, Deibel Jr MR, Dunn CJ, et al. Purification, cloning, expression and biological characterization of an interleukin-1 receptor antagonist protein. Nature 1990; 344: 633–8

    PubMed  CAS  Google Scholar 

  161. Malyak M, Swaney RE, Arend WP. Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Arthritis Rheum 1993; 36: 781–9

    PubMed  CAS  Google Scholar 

  162. Krzesicki RF, Hatfield CA, Bienkowski MJ, et al. Regulation of expression of IL-1 receptor antagonist protein in human synovial and dermal fibroblasts. J Immunol 1993; 150: 4008–18

    PubMed  CAS  Google Scholar 

  163. Lebsack ME, Paul CC, Bloedow DC. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis [abstract]. Arthritis Rheum 1991; 34 Suppl.: S45

    Google Scholar 

  164. Chole RA, Faddis BT, Tinling SP. In vivo inhibition of localized bone resorption by human recombinant interleukin-1 receptor antagonist. J Bone Miner Res 1995; 10: 281–4

    PubMed  CAS  Google Scholar 

  165. Chernajovsky Y, Annenkov A, Herman C, et al. Gene therapy for rheumatoid arthritis: theoretical considerations. Drugs Aging 1998; 12: 29–41

    PubMed  CAS  Google Scholar 

  166. Raz E, Watanabe A, Baird SM, et al. Systemic immunological effects of cytokine genes injected into skeletal muscle. Proc Natl Acad Sci U S A 1993; 90: 4523–7

    PubMed  CAS  Google Scholar 

  167. Koch AE, Kurata H, Hosaka S, et al. Use of the rat adjuvant-induced arthritis as a model for rheumatoid arthritis gene therapy [abstract]. Arthritis Rheum 1996; 39 Suppl.: S248

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Northwestern University Medical School, 303 E. Chicago Avenue, Ward Building 3-315, Chicago, Illinois, 60611, USA

    Zoltan Szekanecz &  Alisa E. Koch

  2. Third Department of Medicine, University Medical School of Debrecen, Debrecen, Hungary

    Zoltan Szekanecz

  3. Lakeside Division, Veterans Administration Chicago Health Care System, Chicago, Illinois, USA

    Alisa E. Koch

  4. Department of Pathology, The University of Michigan Medical Center, Ann Arbor, Michigan, USA

    Steven L. Kunkel

  5. Department of Medicine, The University of Michigan Medical Center, Ann Arbor, Michigan, USA

    Robert M. Strieter

Authors
  1. Zoltan Szekanecz
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alisa E. Koch
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Steven L. Kunkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Robert M. Strieter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Alisa E. Koch.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Szekanecz, Z., Koch, A.E., Kunkel, S.L. et al. Cytokines in Rheumatoid Arthritis. Drugs Aging 12, 377–390 (1998). https://doi.org/10.2165/00002512-199812050-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-199812050-00004

Keywords

Search

Navigation